Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:AKBANASDAQ:ANLNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.54-8.9%$4.56$0.40▼$626.40$5.70M0.26813,342 shs601,030 shsAKBAAkebia Therapeutics$1.93+1.0%$2.06$0.80▼$2.89$455.93M0.952.75 million shs3.21 million shsANLAdlai Nortye$2.09-2.3%$2.20$1.85▼$17.48$77.12M-1.5612,377 shs1,158 shsSIGASIGA Technologies$5.50+0.4%$5.81$5.16▼$12.83$392.90M0.98781,737 shs352,846 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma-8.88%-22.72%-11.33%-98.63%-99.90%AKBAAkebia Therapeutics+1.05%+0.52%+7.22%+1.58%+22.15%ANLAdlai Nortye-2.34%-8.93%-9.13%-14.34%-78.12%SIGASIGA Technologies+0.36%-4.01%+2.04%-11.86%-43.01%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.3332 of 5 stars3.50.00.00.01.90.01.9AKBAAkebia Therapeutics3.7156 of 5 stars3.51.00.04.03.00.80.6ANLAdlai Nortye2.5153 of 5 stars3.55.00.00.03.00.00.0SIGASIGA Technologies2.5378 of 5 stars0.03.00.00.02.90.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0066,455.74% UpsideAKBAAkebia Therapeutics 3.00Buy$6.50236.79% UpsideANLAdlai Nortye 3.00Buy$9.00330.62% UpsideSIGASIGA Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANL, AKBA, SIGA, and AEON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.003/14/2025AKBAAkebia TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $6.003/14/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.501/23/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.501/14/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.50(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AAKBAAkebia Therapeutics$160.18M2.85N/AN/A($0.16) per share-12.06ANLAdlai Nortye$5M15.42N/AN/AN/A∞SIGASIGA Technologies$138.72M2.83$0.87 per share6.34$2.77 per share1.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$67.783.01N/AN/AN/AN/A-994.63%4/4/2025 (Estimated)AKBAAkebia Therapeutics-$51.92M-$0.33N/AN/AN/A-27.07%N/A-20.57%5/8/2025 (Estimated)ANLAdlai Nortye-$104.87MN/A0.00N/AN/AN/AN/AN/A4/18/2025 (Estimated)SIGASIGA Technologies$68.07M$0.824.584.40N/A49.33%49.06%38.72%5/6/2025 (Estimated)Latest ANL, AKBA, SIGA, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22AKBAAkebia TherapeuticsN/A1.521.21ANLAdlai NortyeN/A1.85N/ASIGASIGA TechnologiesN/A8.105.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%AKBAAkebia Therapeutics33.92%ANLAdlai Nortye35.21%SIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma7.00%AKBAAkebia Therapeutics4.10%ANLAdlai NortyeN/ASIGASIGA Technologies1.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma510.53 million74.37 millionNot OptionableAKBAAkebia Therapeutics430236.23 million209.24 millionOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableANL, AKBA, SIGA, and AEON HeadlinesRecent News About These CompaniesSIGA Technologies, Inc. (NASDAQ:SIGA) Holdings Lessened by First Wilshire Securities Management Inc.April 3 at 6:24 AM | marketbeat.comAltraVue Capital LLC Buys 326,630 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)April 2 at 6:11 AM | marketbeat.comFY2025 Earnings Forecast for SIGA Issued By Edison Inv. ResMarch 31 at 1:51 AM | americanbankingnews.comBrokers Offer Predictions for SIGA FY2025 EarningsMarch 31 at 1:48 AM | marketbeat.comCharles Schwab Investment Management Inc. Cuts Position in SIGA Technologies, Inc. (NASDAQ:SIGA)March 28, 2025 | marketbeat.comBank of New York Mellon Corp Has $1.74 Million Stake in SIGA Technologies, Inc. (NASDAQ:SIGA)March 23, 2025 | marketbeat.comInvestors Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)March 20, 2025 | marketbeat.comSiga Technologies Inc. (SIGA) Stock Slides as Market Rises: Facts to Know Before You TradeMarch 19, 2025 | zacks.comSIGA Technologies, Inc. (NASDAQ:SIGA) Sees Large Growth in Short InterestMarch 18, 2025 | marketbeat.comSIGA Technologies Appoints Retired General John Keane to Board of DirectorsMarch 18, 2025 | quiverquant.comSIGA Appoints Retired General John M. Keane to its Board of DirectorsMarch 18, 2025 | globenewswire.com48,177 Shares in SIGA Technologies, Inc. (NASDAQ:SIGA) Purchased by Vestcor IncMarch 18, 2025 | marketbeat.comVictory Capital Management Inc. Acquires 49,355 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)March 18, 2025 | marketbeat.comSiga Technologies Inc. (SIGA) Rises Higher Than Market: Key FactsMarch 17, 2025 | zacks.comNIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II MpoxMarch 12, 2025 | markets.businessinsider.comSIGA Technologies (NASDAQ:SIGA) Posts Earnings ResultsMarch 12, 2025 | marketbeat.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comQ4 2024 SIGA Technologies Inc Earnings CallMarch 12, 2025 | finance.yahoo.comSIGA Technologies, Inc. (SIGA) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024March 11, 2025 | globenewswire.comKenox and Lactiga partner on sIgA therapies for immunodeficiencyMarch 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingDelta’s Stock Takes a Hit—Can Lower Oil Prices Fuel a Comeback?By Jea Yu | March 19, 2025View Delta’s Stock Takes a Hit—Can Lower Oil Prices Fuel a Comeback?ANL, AKBA, SIGA, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.54 -0.05 (-8.88%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.53 -0.01 (-2.38%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Akebia Therapeutics NASDAQ:AKBA$1.93 +0.02 (+1.05%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.85 -0.08 (-4.15%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Adlai Nortye NASDAQ:ANL$2.09 -0.05 (-2.34%) As of 04/2/2025 03:59 PM EasternAdlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.SIGA Technologies NASDAQ:SIGA$5.50 +0.02 (+0.36%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$5.42 -0.08 (-1.45%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
